Ruben Argueta - Quidel Director Relations
| QDEL Stock | USD 41.35 0.25 0.60% |
Insider
Ruben Argueta is Director Relations of Quidel
| Address | 9975 Summers Ridge Road, San Diego, CA, United States, 92121 |
| Phone | 858 552 1100 |
| Web | https://www.quidelortho.com |
Quidel Management Efficiency
The company has return on total asset (ROA) of 0.0104 % which means that it generated a profit of $0.0104 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4579) %, meaning that it created substantial loss on money invested by shareholders. Quidel's management efficiency ratios could be used to measure how well Quidel manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is expected to rise to 0.02 this year, although the value of Return On Tangible Assets will most likely fall to (0). At this time, Quidel's Intangible Assets are quite stable compared to the past year. Other Assets is expected to rise to about 477.9 M this year, although the value of Deferred Long Term Asset Charges will most likely fall to about 25.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Laura MBA | Si Bone | 57 | |
| Collin DSilva | Bruker | 67 | |
| Mitchell Hill | Inari Medical | 65 | |
| Georgia Melenikiotou | Inspire Medical Systems | 61 | |
| Rebecca Kuhn | Neuropace | 63 | |
| Martha Morrell | Neuropace | 67 | |
| Marco Dolci | LivaNova PLC | 62 | |
| Stacey Desrochers | Bruker | N/A | |
| Urban Faeh | Bruker | N/A | |
| John Rondoni | Inspire Medical Systems | 44 | |
| Leana Wen | Glaukos Corp | 37 | |
| Laverne Council | CONMED | 59 | |
| Janet Byk | Inari Medical | N/A | |
| Ross Sylvia | Tandem Diabetes Care | N/A | |
| Paul Flynn | DexCom Inc | 55 | |
| Denice Torres | Glaukos Corp | 60 | |
| Lauren Budden | Insulet | 49 | |
| Thomas MD | Inari Medical | 51 | |
| Barbara Schwarzentraub | CONMED | 53 | |
| Andre Marquette | Neuropace | N/A | |
| Lisa Paul | Pulmonx Corp | 60 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | 0.0104 |
Quidel Leadership Team
Elected by the shareholders, the Quidel's board of directors comprises two types of representatives: Quidel inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quidel. The board's role is to monitor Quidel's management team and ensure that shareholders' interests are well served. Quidel's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quidel's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ruben Argueta, Director Relations | ||
| Juliet Cunningham, Vice Relations | ||
| Michelle JD, Chief Officer | ||
| Chockalingam Palaniappan, Chief Officer | ||
| Joseph CPA, Chief Officer | ||
| Louise Brandy, Senior Officer | ||
| Tamara Ranalli, Molecular Leader | ||
| Phillip Askim, Associate VP | ||
| Patrick Klein, Senior Officer | ||
| Ronald Bowman, Chief Officer | ||
| William Ferenczy, Point Leader | ||
| Jonathan Siegrist, Executive CTO | ||
| Philip McLellan, Chief Officer | ||
| Douglas Bryant, CEO and President and Director | ||
| Brian Blaser, CEO President | ||
| Werner Kroll, Senior Development | ||
| Robert JD, Executive President | ||
| Michelle Hodges, General VP | ||
| Michael Iskra, Executive Officer |
Quidel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Quidel a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | 0.0104 | ||||
| Profit Margin | (0.66) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 5.39 B | ||||
| Shares Outstanding | 67.26 M | ||||
| Shares Owned By Insiders | 1.46 % | ||||
| Shares Owned By Institutions | 96.96 % | ||||
| Number Of Shares Shorted | 3.91 M | ||||
| Price To Earning | 5.56 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quidel. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Quidel Stock please use our How to buy in Quidel Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quidel. If investors know Quidel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quidel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (27.81) | Revenue Per Share 42.04 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0104 |
The market value of Quidel is measured differently than its book value, which is the value of Quidel that is recorded on the company's balance sheet. Investors also form their own opinion of Quidel's value that differs from its market value or its book value, called intrinsic value, which is Quidel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quidel's market value can be influenced by many factors that don't directly affect Quidel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quidel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quidel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quidel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.